{"id":8458,"date":"2026-09-17T13:21:56","date_gmt":"2026-09-17T17:21:56","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/pipeline\/"},"modified":"2026-10-25T14:41:15","modified_gmt":"2026-10-25T18:41:15","slug":"pipeline","status":"publish","type":"page","link":"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mr9fdup2-7a5b57e32b730f9363dee9c8edc8db4d\">\n.avia-section.av-mr9fdup2-7a5b57e32b730f9363dee9c8edc8db4d{\nbackground-color:#0e1539;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_1'  class='avia-section av-mr9fdup2-7a5b57e32b730f9363dee9c8edc8db4d main_color avia-section-huge avia-no-border-styling  avia-builder-el-0  el_before_av_section  avia-builder-el-first  page-banner unset-row video-bg-banner gradient-from-bottom avia-bg-style-scroll av-section-with-video-bg container_wrap sidebar_right'   data-section-video-ratio='16:9'><div  class='avia-slideshow av_slideshow_obj-1-6ae3fad56279a avia-slideshow-featured av_slideshow avia-slide-slider av-slideshow-ui av-control-default av-slideshow-manual av-loop-once av-loop-manual-endless av-default-height-applied  av-section-video-bg avia-slideshow-1' data-slideshow-options=\"{&quot;animation&quot;:&quot;slide&quot;,&quot;autoplay&quot;:false,&quot;loop_autoplay&quot;:&quot;once&quot;,&quot;interval&quot;:5,&quot;loop_manual&quot;:&quot;manual-endless&quot;,&quot;autoplay_stopper&quot;:false,&quot;noNavigation&quot;:false,&quot;bg_slider&quot;:false,&quot;keep_padding&quot;:false,&quot;hoverpause&quot;:false,&quot;show_slide_delay&quot;:0}\"  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\" ><ul class='avia-slideshow-inner ' style='padding-bottom: 28.6666666667%;'><li  data-controls='disabled' data-mute='aviaTBaviaTBvideo_mute' data-loop='1' data-disable-autoplay=''  data-video-ratio='1.77777777778' class='avia-slideshow-slide av_slideshow_obj-1-6ae3fad56279a__0  av-video-slide  av-video-service-html5  av-hide-video-controls av-mute-video av-loop-video  av-single-slide slide-1 slide-odd'><div data-rel='slideshow-1' class='avia-slide-wrap '    itemprop=\"video\" itemtype=\"https:\/\/schema.org\/VideoObject\" ><div class='av-click-overlay'><\/div><video class='avia_video'  autoplay playsinline loop preload=\"metadata\" muted  id='player_8458_836592686_465745243'><source src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/09\/Homepage-Hero-Helix.mp4\" type=\"video\/mp4\" \/><\/video><div class=\"av-click-to-play-overlay\"><div class=\"avia_playpause_icon\"><\/div><\/div><\/div><\/li><\/ul><\/div><div class='container av-section-cont-open' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-8458'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-1lr9p-9e90dd5e175d3fd6b6431ed283fe2041\">\n.avia-image-container.av-1lr9p-9e90dd5e175d3fd6b6431ed283fe2041 img.avia_image{\nbox-shadow:none;\n}\n.avia-image-container.av-1lr9p-9e90dd5e175d3fd6b6431ed283fe2041 .av-image-caption-overlay-center{\ncolor:#ffffff;\n}\n<\/style>\n<div  class='avia-image-container av-1lr9p-9e90dd5e175d3fd6b6431ed283fe2041 av-styling- av-hover-fade avia-align-center  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  bottom-right-dots-img animated-dots flip-dots'   itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\" ><div class=\"avia-image-container-inner\"><div class=\"avia-image-overlay-wrap\"><img decoding=\"async\" fetchpriority=\"high\" class='wp-image-8016 avia-img-lazy-loading-not-8016 avia_image fade-basic' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-1.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><img decoding=\"async\" class='wp-image-8019 avia-img-lazy-loading-not-8019 avia_image fade-overlay' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-2.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><\/div><\/div><\/div>\n<div  class='flex_column av-71rlh-763afbc60e6a6aec3b89829634426995 av_three_fifth  avia-builder-el-2  el_after_av_image  avia-builder-el-last  first flex_column_div av-animated-generic fade-in  '     ><section  class='av_textblock_section av-mr9f6zqa-289cfa14752f8348df4fd4b631d71519 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock page-banner-content'  itemprop=\"text\" ><h1>Pipeline<\/h1>\n<p>GenSight Biologics compte deux candidats-m\u00e9dicaments en d\u00e9veloppement clinique dans les maladies r\u00e9tiniennes h\u00e9r\u00e9ditaires qui entra\u00eenent une perte de la vue s\u00e9v\u00e8re. Ces produits associent la th\u00e9rapie g\u00e9nique \u00e0 des technologies propri\u00e9taires, dans le but de pr\u00e9server et restaurer la fonction visuelle.<\/p>\n<\/div><\/section><\/div>\n\n<\/div><\/div><\/main><!-- close content main element --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-qhw2l-bcf9de2a9177b215d542631b7657aabb\">\n.avia-section.av-qhw2l-bcf9de2a9177b215d542631b7657aabb{\nbackground-color:#0e1539;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_2'  class='avia-section av-qhw2l-bcf9de2a9177b215d542631b7657aabb main_color avia-section-large avia-no-border-styling  avia-builder-el-4  el_after_av_section  el_before_av_section  unset-row flex-row extra-padding-bottom avia-bg-style-scroll container_wrap sidebar_right'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-8458'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-n99rp-8493c0427dfed67de071f95534a3338a\">\n.avia-image-container.av-n99rp-8493c0427dfed67de071f95534a3338a img.avia_image{\nbox-shadow:none;\n}\n.avia-image-container.av-n99rp-8493c0427dfed67de071f95534a3338a .av-image-caption-overlay-center{\ncolor:#ffffff;\n}\n<\/style>\n<div  class='avia-image-container av-n99rp-8493c0427dfed67de071f95534a3338a av-styling- av-hover-fade avia-align-center  avia-builder-el-5  el_before_av_one_full  avia-builder-el-first  invalid-custom-class-found top-left-dots-img animated-dots'   itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\" ><div class=\"avia-image-container-inner\"><div class=\"avia-image-overlay-wrap\"><img decoding=\"async\" class='wp-image-8016 avia-img-lazy-loading-not-8016 avia_image fade-basic' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-1.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><img decoding=\"async\" class='wp-image-8019 avia-img-lazy-loading-not-8019 avia_image fade-overlay' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-2.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><\/div><\/div><\/div>\n<div  class='flex_column av-equwl-d762321c9f70f40f8e4d4e3d2b12f7b6 av_one_full  avia-builder-el-6  el_after_av_image  avia-builder-el-last  first flex_column_div av-animated-generic bottom-to-top  '     ><section  class='av_textblock_section av-av41h-1864c516b3be1cc0bbe4b540b646a1b2 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><div class=\"pipeline-header-section\">\r\n\t<div class=\"pipeline-columns\">\r\n\t\t<div class=\"pipeline-inner-left-side\">\r\n\t\t\t<div class=\"candidate-name\">\r\n                <div class=\"candidate-label\">Programme<\/div>\r\n            <\/div>\r\n\t\t\t<div class=\"candidate-name\">\r\n                <div class=\"candidate-label\">Plateforme<\/div>\r\n            <\/div>\r\n\t\t<\/div>\r\n\t\t<div class=\"pipeline-inner-right-side\">\r\n\t\t\t<div class=\"right-side-indication\">\r\n                <div class=\"indication-label\">Indication<\/div>\r\n            <\/div>\r\n\t\t\t<div class=\"pipeline-header-labels\">\r\n\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t<div class=\"desktop-label\"> Pr\u00e9clinique <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t<div class=\"desktop-label\">Phase 1 <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t<div class=\"desktop-label\"> Phase 1\/2 <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t<div class=\"desktop-label\"> Phase 2 <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t<div class=\"desktop-label\"> Phase 3 <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t<div class=\"desktop-label\"> Enregistrement <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t<div class=\"desktop-label\"> Commercialisation <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\r\n<div class=\"pipeline-body-section\">\r\n    <div class=\"pipeline-columns accordion-title\">\r\n        <div class=\"pipeline-inner-left-side\">\r\n            <div class=\"pipeline-inner-left-side-content\">\r\n                <div class=\"left-side-label\">\r\n                    <div class=\"sub-label\">GS010 \/ LUMEVOQ\u00ae <\/div>\r\n                <\/div>\r\n\t\t\t\t<div class=\"left-side-label\">\r\n                    <div class=\"sub-label technology\">MTS <\/div>\r\n                <\/div>\r\n            <\/div>\r\n        <\/div>\r\n        <div class=\"pipeline-inner-right-side\">\r\n\t\t\t<div class=\"single-indication\">\r\n\t\t\t\t<div class=\"right-side-indication\">\r\n\t\t\t\t\t<div class=\"indication-label\">NOHL-<em>ND4<\/em> (Neuropathie Optique H\u00e9r\u00e9ditaire de Leber) <\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t<div class=\"right-side-graphic\">\r\n\t\t\t\t\t<div class=\"mobile-labels\">\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Pr\u00e9clinique <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 1 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 1\/2 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 2 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 3 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Enregistrement <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Commercialisation <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"pipeline-backgrounds\">\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"pipeline-pipe\">\r\n\t\t\t\t\t\t<div class=\"pipe-aligner\">\r\n\t\t\t\t\t\t\t<div class=\"animated-pipeline\" style=\"width:61%;\">\r\n\t\t\t\t\t\t\t\t<div class=\"pipeline-text\">Phase 3<\/div>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t<div class=\"mobile-pipeline-text\"><\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n            <\/div>\r\n        <\/div>\r\n\t\t\r\n    <\/div>\r\n\t<div class=\"accordion-content\">\r\n\t\t<p>GS010\/LUMEVOQ\u00ae est une th\u00e9rapie g\u00e9nique exp\u00e9rimentale destin\u00e9e au traitement de la NOHL provoqu\u00e9e par une mutation <em>ND4<\/em>. Maladie mitochondriale la plus r\u00e9pandue au monde, la NOHL entra\u00eene une perte de la vue rapide et le plus souvent irr\u00e9versible, en particulier chez les jeunes adultes. Gr\u00e2ce \u00e0 notre plateforme propri\u00e9taire MTS, GS010 d\u00e9livre une prot\u00e9ine <em>ND4<\/em> fonctionnelle directement dans les mitochondries et s'attaque ainsi \u00e0 la maladie \u00e0 sa source. GS010 est administr\u00e9 en une seule injection intravitr\u00e9enne par \u0153il. <\/p>\r\n\t\t<p>GS010\/LUMEVOQ\u00ae n'a obtenu d'autorisation de mise sur le march\u00e9 dans aucun pays et n'est pas disponible commercialement. Sous r\u00e9serve de la disponibilit\u00e9 du produit, de certaines conditions r\u00e9glementaires et de l'autorisation des autorit\u00e9s nationales ou locales comp\u00e9tentes, GS010 peut \u00eatre accessible dans le cadre d'acc\u00e8s d\u00e9rogatoires. Pour information sur l'acc\u00e8s compassionnel en France, <a class=\"early-access\" href=\"#\">cliquez ici<\/a>.<\/p>\r\n\t\t<div id=\"ninja_dt_parent_8870\"\n     class=\"ninja-tables-dt-wrapper ninja_table_wrapper loading_ninja_table  ninja-dt-table-container ninja_table_search_disabled ninja_search_right ninja_table_pro nt_type_legacy_table ninja_stacked_no_cell_border dt_hide_vertical_borders ninja-dt-paging-right\">\n\n    \n    \n    \n    <table data-ninja_table_instance=\"ninja_dt_instance_0\"\n           id=\"ninja_dt_8870\"\n           data-unique_identifier=\"ninja_dt_unique_id_3264117628_8870\"\n           class=\"ninja-dt-table ninja_datatable dt_table_8870 ninja_dt_unique_id_3264117628_8870\"\n           style=\"width:100%\"\n           aria-label=\"GS010 \/ LUMEVOQ\u00ae (FR)\">\n                <thead>\n            <tr>\n                                                            <th class=\"ninja_column_0 ninja_clmn_nm_trials\"\n                            >\n                            Essai clinique                        <\/th>\n                                                                                <th class=\"ninja_column_1 ninja_clmn_nm_administration_method\"\n                                                            style=\"width: 30%\"\n                            >\n                            Objectif                        <\/th>\n                                                                                <th class=\"ninja_column_2 ninja_clmn_nm_phase\"\n                            >\n                            Phase                        <\/th>\n                                                                                <th class=\"ninja_column_3 ninja_clmn_nm_status\"\n                            >\n                            Statut                        <\/th>\n                                                                                <th class=\"ninja_column_4 ninja_clmn_nm_clinical_trials\"\n                            >\n                            D\u00e9tails                        <\/th>\n                                                <\/tr>\n        <\/thead>\n        <tbody>\n        <\/tbody>\n    <\/table>\n\n    \n    \n<\/div>\n\t\t<div class=\"table-subtext\">\r\n\t\t\t<h3>Justification de l\u2019\u00e9tude clinique REVISE :<\/h3>\r\n\t\t\t<p>L'essai de phase 2 REVISE r\u00e9pond \u00e0 une demande de l'ANSM de fournir davantage de donn\u00e9es sur la dose du produit \u00e0 injecter, \u00e0 la suite de notre d\u00e9cision de changer la m\u00e9thode de dosage servant \u00e0 mesurer la concentration du virus th\u00e9rapeutique dans les flacons de GS010. Ce nouveau test, qui servira \u00e0 lib\u00e9rer les futurs lots, repose sur une m\u00e9thode plus robuste (moins variable) que celle disponible au d\u00e9but de nos pr\u00e9c\u00e9dents essais de phase 3.<\/p><\/div>\r\n\t\t<br\/>\r\n\t\t<div>\t\r\n\t\t\t<h3>Justification de l'essai clinique RECOVER : <\/h3>\r\n\t\t\t<p>Les pr\u00e9c\u00e9dents essais de Phase 3 (RESCUE, REVERSE et REFLECT) n'ont pas pu atteindre le crit\u00e8re d'efficacit\u00e9 pr\u00e9d\u00e9fini, en raison d'une d\u00e9couverte scientifique issue de ces m\u00eames essais : lorsque l'un des yeux d'un patient \u00e9tait trait\u00e9 par la th\u00e9rapie g\u00e9nique GS010, l'\u0153il non trait\u00e9 s'am\u00e9liorait lui aussi de fa\u00e7on significative (\u00ab effet controlat\u00e9ral \u00bb). <\/p>\r\n\t\t\t<p>Ce r\u00e9sultat inattendu a supprim\u00e9 de fait le groupe t\u00e9moin (les yeux trait\u00e9s par injection simul\u00e9e), tel qu'il avait \u00e9t\u00e9 convenu avec les agences r\u00e9glementaires. Con\u00e7u en concertation avec les agences r\u00e9glementaires am\u00e9ricaine et europ\u00e9enne, RECOVER vise \u00e0 d\u00e9montrer l'efficacit\u00e9 d'injections bilat\u00e9rales de GS010 par rapport \u00e0 un groupe placebo : sa m\u00e9thodologie neutralise l'effet de confusion li\u00e9 \u00e0 l'effet controlat\u00e9ral, tout en garantissant un essai correctement contr\u00f4l\u00e9.<\/p>\r\n\t\t<\/div>\r\n\t\t<\/div>\r\n<\/div>\r\n<div class=\"pipeline-body-section\">\r\n    <div class=\"pipeline-columns accordion-title\">\r\n        <div class=\"pipeline-inner-left-side\">\r\n            <div class=\"pipeline-inner-left-side-content\">\r\n                <div class=\"left-side-label\">\r\n                    <div class=\"sub-label\">GS030<\/div>\r\n                <\/div>\r\n\t\t\t\t<div class=\"left-side-label\">\r\n                    <div class=\"sub-label technology\">Optog\u00e9n\u00e9tique<\/div>\r\n                <\/div>\r\n            <\/div>\r\n        <\/div>\r\n        <div class=\"pipeline-inner-right-side\">\r\n\t\t\t<div class=\"single-indication\">\r\n\t\t\t\t<div class=\"right-side-indication\">\r\n\t\t\t\t\t<div class=\"indication-label\">R\u00e9tinite Pigmentaire (RP)<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t<div class=\"right-side-graphic\">\r\n\t\t\t\t\t<div class=\"mobile-labels\">\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Pr\u00e9clinique <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 1 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 1\/2 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 2 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Phase 3 <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Enregistrement <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<div class=\"column\">\r\n\t\t\t\t\t\t\t<div class=\"mobile-label-text\"> Commercialisation <\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"pipeline-backgrounds\">\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t\t<div class=\"column\"> <\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<div class=\"pipeline-pipe\">\r\n\t\t\t\t\t\t<div class=\"pipe-aligner\">\r\n\t\t\t\t\t\t\t<div class=\"animated-pipeline\" style=\"width: 37%;\">\r\n\t\t\t\t\t\t\t\t<div class=\"pipeline-text\">Phase 1\/2<\/div>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t<div class=\"mobile-pipeline-text\"><\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n            <\/div>\r\n        <\/div>\r\n    <\/div>\r\n\t<div class=\"accordion-content\">\r\nGS030 est une th\u00e9rapie optog\u00e9n\u00e9tique exp\u00e9rimentale destin\u00e9e au traitement de la RP, un groupe de maladies r\u00e9tiniennes h\u00e9r\u00e9ditaires (pouvant \u00eatre caus\u00e9es par plus de 100 g\u00e8nes) qui entra\u00eenent une perte progressive de la vue, jusqu'\u00e0 la c\u00e9cit\u00e9. Reposant sur l'optog\u00e9n\u00e9tique, GS030 adopte une approche ind\u00e9pendante de la mutation en cause : elle contourne enti\u00e8rement les photor\u00e9cepteurs endommag\u00e9s en rendant sensibles \u00e0 la lumi\u00e8re les cellules ganglionnaires r\u00e9tiniennes intactes. GS030 consiste en une seule injection intravitr\u00e9enne par \u0153il, suivie du port d'un dispositif de stimulation lumineuse. \r\n\t\t<div id=\"ninja_dt_parent_8872\"\n     class=\"ninja-tables-dt-wrapper ninja_table_wrapper loading_ninja_table  ninja-dt-table-container ninja_table_search_disabled ninja_search_right ninja_table_pro nt_type_legacy_table dt_hide_vertical_borders ninja-dt-paging-right\">\n\n    \n    \n    \n    <table data-ninja_table_instance=\"ninja_dt_instance_1\"\n           id=\"ninja_dt_8872\"\n           data-unique_identifier=\"ninja_dt_unique_id_1460661090_8872\"\n           class=\"ninja-dt-table ninja_datatable dt_table_8872 ninja_dt_unique_id_1460661090_8872\"\n           style=\"width:100%\"\n           aria-label=\"GS030 (FR)\">\n                <thead>\n            <tr>\n                                                            <th class=\"ninja_column_0 ninja_clmn_nm_trials\"\n                            >\n                            Essai clinique                        <\/th>\n                                                                                <th class=\"ninja_column_1 ninja_clmn_nm_administration_method\"\n                                                            style=\"width: 30%\"\n                            >\n                            Objectif                        <\/th>\n                                                                                <th class=\"ninja_column_2 ninja_clmn_nm_phase\"\n                            >\n                            Phase                        <\/th>\n                                                                                <th class=\"ninja_column_3 ninja_clmn_nm_status\"\n                            >\n                            Statut                        <\/th>\n                                                                                <th class=\"ninja_column_4 ninja_clmn_nm_clinical_trials\"\n                            >\n                            D\u00e9tails                        <\/th>\n                                                <\/tr>\n        <\/thead>\n        <tbody>\n        <\/tbody>\n    <\/table>\n\n    \n    \n<\/div>\n\t\t<\/div>\r\n<\/div>\n<\/div><\/section><\/div>\n\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mr9sow68-2a6d22da38f0e3a2aed5d48b9eb9951e\">\n.avia-section.av-mr9sow68-2a6d22da38f0e3a2aed5d48b9eb9951e{\nbackground-color:#0d304e;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_3'  class='avia-section av-mr9sow68-2a6d22da38f0e3a2aed5d48b9eb9951e main_color avia-section-default avia-no-border-styling  avia-builder-el-8  el_after_av_section  avia-builder-el-last  avia-bg-style-scroll container_wrap sidebar_right'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-8458'><div class='entry-content-wrapper clearfix'>\n<div  class='flex_column av-xmfx-ccb0fe5bb9face80ad118c27833dea0b av_one_full  avia-builder-el-9  avia-builder-el-no-sibling  first flex_column_div av-animated-generic fade-in  '     ><section  class='av_textblock_section av-mr9sp6gd-0db82d5b6acaaafc93026d1166d9f069 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock link-with-arrow'  itemprop=\"text\" ><h3 style=\"text-align: center;\">D\u00e9couvrez les technologies au c\u0153ur de notre pipeline<\/h3>\n<\/div><\/section><br \/>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mr9su1yu-facdb7b5b07adeb68c7e6bb9ed59d4f1\">\n#top .hr.hr-invisible.av-mr9su1yu-facdb7b5b07adeb68c7e6bb9ed59d4f1{\nheight:30px;\n}\n<\/style>\n<div  class='hr av-mr9su1yu-facdb7b5b07adeb68c7e6bb9ed59d4f1 hr-invisible  avia-builder-el-11  el_after_av_textblock  el_before_av_buttonrow '><span class='hr-inner '><span class=\"hr-inner-style\"><\/span><\/span><\/div><br \/>\n<div  class='avia-buttonrow-wrap av-mr9sso8b-8e5a69f16530a4b603a2616c70a8e8e5 avia-buttonrow-center  avia-builder-el-12  el_after_av_hr  avia-builder-el-last '>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mr9ssnhl-cc2e6c8b2c4a964e3009e5f646740f8d\">\n#top #wrap_all .avia-button.av-mr9ssnhl-cc2e6c8b2c4a964e3009e5f646740f8d{\nmargin-bottom:5px;\nmargin-right:3px;\nmargin-left:3px;\n}\n<\/style>\n<a href='https:\/\/www.gensight-biologics.com\/fr\/technologie\/mitochondrial-targeting-sequence-mts\/'  class='avia-button av-mr9ssnhl-cc2e6c8b2c4a964e3009e5f646740f8d avia-icon_select-yes-right-icon avia-size-small avia-color-light'   aria-label=\"MTS (Mitochondrial Targeting Sequence)\"><span class='avia_iconbox_title' >MTS (Mitochondrial Targeting Sequence)<\/span><span class='avia_button_icon avia_button_icon_right avia-svg-icon avia-font-svg_entypo-fontello' data-av_svg_icon='right-open-mini' data-av_iconset='svg_entypo-fontello'><svg version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"8\" height=\"32\" viewBox=\"0 0 8 32\" preserveAspectRatio=\"xMidYMid meet\" aria-labelledby='av-svg-title-1' aria-describedby='av-svg-desc-1' role=\"graphics-symbol\">\n<title id='av-svg-title-1'>Right-open-mini<\/title>\n<desc id='av-svg-desc-1'>Right-open-mini<\/desc>\n<path d=\"M0.416 21.44l5.056-5.44-5.056-5.504q-0.832-0.832 0-1.536 0.832-0.832 1.536 0l6.144 6.208q0.768 0.832 0 1.6l-6.144 6.208q-0.704 0.832-1.536 0-0.832-0.704 0-1.536z\"><\/path>\n<\/svg><\/span><\/a>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mr9ssbnu-c2c6fdd0d1cd95e697389fd6f50ecee5\">\n#top #wrap_all .avia-button.av-mr9ssbnu-c2c6fdd0d1cd95e697389fd6f50ecee5{\nmargin-bottom:5px;\nmargin-right:3px;\nmargin-left:3px;\n}\n<\/style>\n<a href='https:\/\/www.gensight-biologics.com\/fr\/technologie\/optogenetics\/'  class='avia-button av-mr9ssbnu-c2c6fdd0d1cd95e697389fd6f50ecee5 avia-icon_select-yes-right-icon avia-size-small avia-color-light'   aria-label=\"Optog\u00e9n\u00e9tique\"><span class='avia_iconbox_title' >Optog\u00e9n\u00e9tique<\/span><span class='avia_button_icon avia_button_icon_right avia-svg-icon avia-font-svg_entypo-fontello' data-av_svg_icon='right-open-mini' data-av_iconset='svg_entypo-fontello'><svg version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"8\" height=\"32\" viewBox=\"0 0 8 32\" preserveAspectRatio=\"xMidYMid meet\" aria-labelledby='av-svg-title-2' aria-describedby='av-svg-desc-2' role=\"graphics-symbol\">\n<title id='av-svg-title-2'>Right-open-mini<\/title>\n<desc id='av-svg-desc-2'>Right-open-mini<\/desc>\n<path d=\"M0.416 21.44l5.056-5.44-5.056-5.504q-0.832-0.832 0-1.536 0.832-0.832 1.536 0l6.144 6.208q0.768 0.832 0 1.6l-6.144 6.208q-0.704 0.832-1.536 0-0.832-0.704 0-1.536z\"><\/path>\n<\/svg><\/span><\/a>\n<\/div><\/p><\/div>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='after_section_3'  class='main_color av_default_container_wrap container_wrap sidebar_right'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-8458'><div class='entry-content-wrapper clearfix'>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-8458","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pipeline de th\u00e9rapie g\u00e9nique | GenSight Biologics<\/title>\n<meta name=\"description\" content=\"D\u00e9couvrez le d\u00e9veloppement clinique des candidats-m\u00e9dicaments de GenSight Biologics : GS010 dans la NOHL et GS030 dans la r\u00e9tinite pigmentaire.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pipeline de th\u00e9rapie g\u00e9nique | GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"D\u00e9couvrez le d\u00e9veloppement clinique des candidats-m\u00e9dicaments de GenSight Biologics : GS010 dans la NOHL et GS030 dans la r\u00e9tinite pigmentaire.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-25T18:41:15+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/pipeline\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/pipeline\\\/\",\"name\":\"Pipeline de th\u00e9rapie g\u00e9nique | GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-09-17T17:21:56+00:00\",\"dateModified\":\"2026-10-25T18:41:15+00:00\",\"description\":\"D\u00e9couvrez le d\u00e9veloppement clinique des candidats-m\u00e9dicaments de GenSight Biologics : GS010 dans la NOHL et GS030 dans la r\u00e9tinite pigmentaire.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/pipeline\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/pipeline\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pipeline de th\u00e9rapie g\u00e9nique | GenSight Biologics","description":"D\u00e9couvrez le d\u00e9veloppement clinique des candidats-m\u00e9dicaments de GenSight Biologics : GS010 dans la NOHL et GS030 dans la r\u00e9tinite pigmentaire.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/","og_locale":"fr_FR","og_type":"article","og_title":"Pipeline de th\u00e9rapie g\u00e9nique | GenSight Biologics","og_description":"D\u00e9couvrez le d\u00e9veloppement clinique des candidats-m\u00e9dicaments de GenSight Biologics : GS010 dans la NOHL et GS030 dans la r\u00e9tinite pigmentaire.","og_url":"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/","og_site_name":"GenSight Biologics","article_modified_time":"2026-10-25T18:41:15+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/","url":"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/","name":"Pipeline de th\u00e9rapie g\u00e9nique | GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-09-17T17:21:56+00:00","dateModified":"2026-10-25T18:41:15+00:00","description":"D\u00e9couvrez le d\u00e9veloppement clinique des candidats-m\u00e9dicaments de GenSight Biologics : GS010 dans la NOHL et GS030 dans la r\u00e9tinite pigmentaire.","breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages\/8458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=8458"}],"version-history":[{"count":17,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages\/8458\/revisions"}],"predecessor-version":[{"id":9324,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages\/8458\/revisions\/9324"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=8458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}